U.S. stock futures opened sharply lower Monday as an escalation in the Middle East conflict lifted energy prices, prompting renewed concern about the outlook for economic growth.
Premarket trading featured a wide set of movers across healthcare, technology, and energy. Several smaller names posted large percentage moves, while some blue-chip health and life-science companies registered declines ahead of results or following clinical and corporate news.
Notable premarket movers
- Hims & Hers Health - The telehealth platform's shares surged 43% after reports that Novo Nordisk plans to distribute its weight-loss drugs through the service, a development described as a surprising reconciliation following a recent legal dispute between the two companies.
- Hewlett Packard Enterprise - Shares fell 1.3% ahead of the company's first-quarter results. Street expectations center on roughly 19-20% year-over-year revenue growth to about $9.3 billion, with AI infrastructure demand cited as a driver of those projections.
- Pfizer - The drugmaker's stock declined 1.6% after it released results from a mid-stage clinical trial of an experimental antibody treatment for atopic dermatitis.
- Agilent Technologies - The life sciences firm slipped 1.4% after announcing an all-cash acquisition of privately held clinical pathology company Biocare Medical in a deal valued at $950 million.
- Aureus Greenway - Shares jumped 47% following a report that the holding company will merge with Powerus, a drone manufacturer reportedly backed by President Trump’s sons.
- Relmada Therapeutics - The pharmaceutical company rallied 32% after announcing 12-month interim data from its Phase 2 trial in patients with high-risk non-muscle invasive bladder cancer.
- Exxon Mobil and Chevron - Both majors gained around 1% as crude oil surged, with Brent trading above $110 a barrel amid the geopolitical escalation.
One promotional note highlighted an AI-driven equity screening tool that evaluates Chevron (CVX) among other names using more than 100 financial metrics and referenced historical winners identified by the system; the tool poses the question of whether investors should be buying CVX now.
The mix of strong moves in smaller healthcare and biotech stocks, declines tied to clinical or corporate announcements, and gains for large oil producers underscores the market's sensitivity to both company-level catalysts and broader geopolitical developments that feed through to energy markets.